23andMe, Genetech enter $50M deal

 

Pharmaceutical company Genetech is expected to pay as much as $50 million to 23andMe to access its genetic data donated by consumers, reports The Verge.

In 2013, 23andMe was prohibited from selling its saliva test kits after they were judged to be in violation of the FDA’s marketing guidelines. However, before that took place the company already had attracted about 800,000 customers, of which three-quarters had consented to utilize their data anonymously for medical research, according to the story.

Read more below:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.